Summary of the STEP-HFpEF trial 2023 published in Nature Medicine

• The STEP-HFpEF trial was a study of semaglutide in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF).
• Semaglutide improved symptoms, physical limitations, exercise function, and reduced body weight in patients with HFpEF and obesity.
• The benefits of semaglutide were consistent across obesity categories.
• The magnitude of the benefit of semaglutide was directly related to the extent of weight loss.
• Patients who received semaglutide had a 16.6-point improvement in their Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS), compared to an 8.7-point improvement in the placebo group.

• Patients who received semaglutide walked an additional 21.5 meters in the 6-minute walk test, compared to 1.2 meters in the placebo group.
• Patients who received semaglutide had a 43.5% reduction in their C-reactive protein (CRP) levels, compared to a 7.3% reduction in the placebo group.

Overall, the STEP-HFpEF trial showed that semaglutide is a promising treatment option for patients with the obesity phenotype of HFpEF. Semaglutide improved these patients' symptoms, physical limitations, exercise function, and reduced body weight. The magnitude of the benefit was directly related to the extent of weight loss.

Link to the article: https://doi.org/10.1038/s41591-023-02526-x

---

Send in a voice message: https://podcasters.spotify.com/pod/show/dr-bishnu-subedi/message